NovaBay Pharmaceuticals, Inc. (NYSE:NBY) Major Shareholder Poplar Point Capital Partners Buys 70,685 Shares

Posted by Doug Wharley on Apr 15th, 2025

NovaBay Pharmaceuticals, Inc. (NYSE:NBY – Get Free Report) major shareholder Poplar Point Capital Partners bought 70,685 shares of NovaBay Pharmaceuticals stock in a transaction on Friday, January 31st. The shares were bought at an average price of $0.65 per share, for a total transaction of $45,945.25. Following the acquisition, the insider now owns 620,685 shares of the company’s stock, valued at approximately $403,445.25. The trade was a 12.85 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Major shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Poplar Point Capital Partners also recently made the following trade(s):

On Monday, January 27th, Poplar Point Capital Partners purchased 31,703 shares of NovaBay Pharmaceuticals stock. The stock was purchased at an average price of $0.69 per share, for a total transaction of $21,875.07.
On Thursday, February 20th, Poplar Point Capital Partners bought 1,836 shares of NovaBay Pharmaceuticals stock. The stock was purchased at an average cost of $0.63 per share, with a total value of $1,156.68.
On Tuesday, February 18th, Poplar Point Capital Partners acquired 3,222 shares of NovaBay Pharmaceuticals stock. The stock was purchased at an average price of $0.66 per share, with a total value of $2,126.52.
On Monday, February 3rd, Poplar Point Capital Partners acquired 2,597 shares of NovaBay Pharmaceuticals stock. The shares were acquired at an average price of $0.64 per share, for a total transaction of $1,662.08.
On Friday, March 7th, Poplar Point Capital Partners purchased 102 shares of NovaBay Pharmaceuticals stock. The stock was purchased at an average price of $0.55 per share, for a total transaction of $56.10.
On Tuesday, March 4th, Poplar Point Capital Partners bought 4,000 shares of NovaBay Pharmaceuticals stock. The stock was acquired at an average cost of $0.58 per share, with a total value of $2,320.00.
On Thursday, February 27th, Poplar Point Capital Partners purchased 385 shares of NovaBay Pharmaceuticals stock. The shares were acquired at an average cost of $0.61 per share, for a total transaction of $234.85.
On Tuesday, February 25th, Poplar Point Capital Partners acquired 25,033 shares of NovaBay Pharmaceuticals stock. The stock was bought at an average price of $0.62 per share, with a total value of $15,520.46.
On Friday, March 14th, Poplar Point Capital Partners purchased 25,511 shares of NovaBay Pharmaceuticals stock. The shares were bought at an average cost of $0.63 per share, with a total value of $16,071.93.
On Wednesday, March 12th, Poplar Point Capital Partners purchased 11,837 shares of NovaBay Pharmaceuticals stock. The shares were bought at an average cost of $0.62 per share, for a total transaction of $7,338.94.

NovaBay Pharmaceuticals Stock Performance

NYSE:NBY traded up $0.04 during mid-day trading on Tuesday, hitting $0.60. The stock had a trading volume of 176,212 shares, compared to its average volume of 188,552. The company’s 50 day simple moving average is $0.60 and its 200 day simple moving average is $0.63. The stock has a market cap of $3.49 million, a price-to-earnings ratio of -0.01 and a beta of 0.90. NovaBay Pharmaceuticals, Inc. has a twelve month low of $0.36 and a twelve month high of $9.08.

Analyst Upgrades and Downgrades

Separately, StockNews.com assumed coverage on NovaBay Pharmaceuticals in a report on Thursday, April 10th. They issued a “hold” rating for the company.

View Our Latest Stock Analysis on NovaBay Pharmaceuticals

NovaBay Pharmaceuticals Company Profile

(Get Free Report)

NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands.